175 related articles for article (PubMed ID: 18669584)
1. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
D'Agostino J; Zhang X; Wu H; Ling G; Wang S; Zhang QY; Liu F; Ding X
Drug Metab Dispos; 2008 Nov; 36(11):2316-23. PubMed ID: 18669584
[TBL] [Abstract][Full Text] [Related]
2. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
3. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL; He XY; Shen J; Wang JS; Hong JY
Toxicol Sci; 2006 Nov; 94(1):38-45. PubMed ID: 16917071
[TBL] [Abstract][Full Text] [Related]
4. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
6. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
7. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
Megaraj V; Zhou X; Xie F; Liu Z; Yang W; Ding X
Carcinogenesis; 2014 Jan; 35(1):131-7. PubMed ID: 23917075
[TBL] [Abstract][Full Text] [Related]
8. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody.
Zhu LR; Thomas PE; Lu G; Reuhl KR; Yang GY; Wang LD; Wang SL; Yang CS; He XY; Hong JY
Drug Metab Dispos; 2006 Oct; 34(10):1672-6. PubMed ID: 16815959
[TBL] [Abstract][Full Text] [Related]
9. CYP2A13 Genetic Polymorphisms in Relation to the Risk of Bladder Cancer in Japanese Smokers.
Kumondai M; Hosono H; Orikasa K; Arai Y; Arai T; Sugimura H; Ozono S; Sugiyama T; Takayama T; Sasaki T; Hirasawa N; Hiratsuka M
Biol Pharm Bull; 2016; 39(10):1683-1686. PubMed ID: 27725446
[TBL] [Abstract][Full Text] [Related]
10. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma.
Chiang HC; Lee H; Chao HR; Chiou YH; Tsou TC
Cancer Epidemiol; 2013 Oct; 37(5):653-9. PubMed ID: 23752126
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
13. Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung.
Zhang X; Caggana M; Cutler TL; Ding X
J Pharmacol Exp Ther; 2004 Oct; 311(1):373-81. PubMed ID: 15175424
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2, and their genetic interaction is associated with lung cancer.
Xiang C; Wang J; Kou X; Chen X; Qin Z; Jiang Y; Sun C; Xu J; Tan W; Jin L; Lin D; He F; Wang H
FASEB J; 2015 May; 29(5):1986-98. PubMed ID: 25667220
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cis-regulatory single nucleotide polymorphisms.
Wu H; Zhang X; Ling G; D'Agostino J; Ding X
Pharmacogenet Genomics; 2009 Nov; 19(11):852-63. PubMed ID: 20431511
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation.
Kumondai M; Hosono H; Maekawa M; Yamaguchi H; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Feb; 33(1):82-89. PubMed ID: 29342418
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of CYP2A13 polymorphisms.
Schlicht KE; Michno N; Smith BD; Scott EE; Murphy SE
Xenobiotica; 2007 Dec; 37(12):1439-49. PubMed ID: 17922361
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers.
Fukami T; Nakajima M; Matsumoto I; Zen Y; Oda M; Yokoi T
Cancer Sci; 2010 Apr; 101(4):1024-8. PubMed ID: 20180810
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant.
Zhang X; Su T; Zhang QY; Gu J; Caggana M; Li H; Ding X
J Pharmacol Exp Ther; 2002 Aug; 302(2):416-23. PubMed ID: 12130698
[TBL] [Abstract][Full Text] [Related]
20. Suppression of pulmonary CYP2A13 expression by carcinogen-induced lung tumorigenesis in a CYP2A13-humanized mouse model.
Liu Z; Megaraj V; Li L; Sell S; Hu J; Ding X
Drug Metab Dispos; 2015 May; 43(5):698-702. PubMed ID: 25710941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
